FY2018 Earnings Estimate for Avrobio Inc (AVRO) Issued By Leerink Swann

Avrobio Inc (NASDAQ:AVRO) – Equities research analysts at Leerink Swann issued their FY2018 earnings estimates for Avrobio in a research note issued on Tuesday, November 27th. Leerink Swann analyst M. Foroohar expects that the company will earn ($3.35) per share for the year. Leerink Swann currently has a “Market Perform” rating on the stock. Leerink Swann also issued estimates for Avrobio’s Q4 2018 earnings at ($0.61) EPS, Q1 2019 earnings at ($0.63) EPS, Q2 2019 earnings at ($0.67) EPS, Q3 2019 earnings at ($0.71) EPS, Q4 2019 earnings at ($0.75) EPS, FY2019 earnings at ($2.74) EPS and FY2020 earnings at ($2.84) EPS.

Avrobio (NASDAQ:AVRO) last posted its quarterly earnings results on Tuesday, November 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.42.

Several other research analysts have also recently issued reports on AVRO. Morgan Stanley increased their price target on shares of Avrobio from $37.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, August 13th. HC Wainwright initiated coverage on shares of Avrobio in a report on Monday, September 17th. They set a “buy” rating for the company. Zacks Investment Research cut shares of Avrobio from a “hold” rating to a “sell” rating in a report on Monday, September 17th. Guggenheim initiated coverage on shares of Avrobio in a report on Tuesday, October 9th. They set a “buy” rating for the company. Finally, ValuEngine cut shares of Avrobio from a “buy” rating to a “hold” rating in a report on Wednesday, October 24th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Avrobio presently has a consensus rating of “Buy” and a consensus price target of $39.50.

NASDAQ AVRO opened at $26.79 on Friday. Avrobio has a 52-week low of $20.30 and a 52-week high of $53.70.

A number of institutional investors and hedge funds have recently modified their holdings of the business. SV Health Investors LLC acquired a new position in Avrobio during the second quarter worth about $78,141,000. JPMorgan Chase & Co. grew its position in Avrobio by 65.1% during the third quarter. JPMorgan Chase & Co. now owns 537,322 shares of the company’s stock worth $27,871,000 after buying an additional 211,847 shares during the period. FMR LLC acquired a new position in Avrobio during the second quarter worth about $14,280,000. Citadel Advisors LLC acquired a new position in Avrobio during the second quarter worth about $12,422,000. Finally, Emerald Advisers Inc. PA grew its position in Avrobio by 57.9% during the third quarter. Emerald Advisers Inc. PA now owns 378,374 shares of the company’s stock worth $19,626,000 after buying an additional 138,714 shares during the period. Institutional investors own 67.57% of the company’s stock.

About Avrobio

AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.

Recommended Story: Reverse Stock Split

Earnings History and Estimates for Avrobio (NASDAQ:AVRO)

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit